1.

Decides to set up a special committee on beating cancer, vested with the following responsibilities: (a) looking at actions to strengthen the approach at every key stage of the disease: prevention, diagnosis, treatment, life as a cancer survivor and palliative care, ensuring a close link with the research mission on cancer in the future Horizon Europe programme and with a focus on EU competence; (b) listening to the current evidence and data available and react by identifying policies and priorities that meet patients’ needs; (c) evaluating the possibilities where, in accordance with the TFEU, the EU can take concrete steps to fight cancer and where only recommendations to the Member States and exchange of best practices are possible and focus on the concrete actions; (d) evaluating scientific knowledge on the best possible prevention of cancer and identifying specific actions, including the strict implementation of current legislation and the identification of future measures in the fields of tobacco control, measures to reduce obesity and improve nutritional choices, measures to reduce alcohol use, measures to increase vaccination and treatment for infections, measures to reduce chemical exposure including cumulative impacts, air pollution as mentioned in the European Green Deal and exposure to carcinogens in the workplace, and measures to protect against radiation; evaluating where possible the quantifiable effects of such measures; (e) analysing and assessing early detection of cancer in the form of screening programmes to ensure that future revisions of the recommendation are incorporated rapidly and efficiently; (f) evaluating the best possible way of supporting research to strengthen prevention, diagnosis, treatment and innovation, especially with a view to achieving the new mission on cancer within Horizon Europe; focusing on areas where Member States alone cannot be successful enough, for example regarding childhood cancer or rare cancers; (g) looking, in particular at ways to support non-profit clinical trials to improve the treatment in areas which the pharmaceutical industry is not investigating because there is limited profitability; (h) assessing the current framework of the pharmaceutical legislation and evaluating if changes are needed to better incentivise genuine innovation and breakthrough treatments for patients, in particular to evaluate possibilities to improve cancer treatment in children and in order to harmonise in the EU the science-based evaluation of efficacy, added value and cost-benefit ratio of each cancer medicine including HPV vaccines and e-health applications; (i) evaluating the possibility of actions, including legislation, to guarantee the development of common standards to enhance the interoperability of health care systems including cancer registers and the necessary eHealth structures to address the different issues of specialised therapies, including avoiding unnecessary travel for patients; (j) evaluating the implementation of the Cross-Border Healthcare Directive and, if necessary, propose improvements to allow patients to see those specialists best suited for their treatment without imposing an unnecessary burden; (k) analysing and assessing the functioning of the European Reference Networks, including their role in gathering and sharing knowledge and best practices in the field of rare cancers prevention and control; (l) evaluating the possibility of EU action to facilitate the transparency of treatment prices to improve the affordability and accessibility of cancer medicines, to avoid drug shortages, and to reduce inequalities between and within Member States; (m) evaluating the possibility, in accordance with the TFEU, of improving patients’ rights, including their rights over their personal data (the right to be forgotten), and their right to non-discrimination — in order to continue their employment and return to work — to access preserved fertility and reproductive treatments, to lifelong surveillance and to optimal palliative care, and to avoid any psychological or financial discrimination due to genetic predisposition to cancers; (n) evaluating the possibility of improving the quality of life for patients and their families; (o) evaluating the possibilities of supporting research in palliative care and of triggering a more intensive exchange of best practice in hospice and palliative care; (p) making any recommendations that it considers necessary with regard to the Union policy on combatting cancer in order to achieve a high level of protection of human health based on the patient oriented approach; to undertake visits and hold hearings to this end with the other EU institutions and relevant agencies, and with international and national institutions, non-governmental organisations and relevant industries, taking into consideration the perspective of a range of stakeholders including practitioners, patients and their loved ones; to recommend how specific EU funds should be mobilized to achieve those goals;